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doi:10.1016/j.ejvs.2009.05.005Abstract Introduction: Inflammatory abdominal aortic aneurysms (IAAAs) have traditionally
been treated by open surgical repair (OSR). Over the last decade, endovascular aneurysm
repair (EVAR) has been increasingly employed. The optimal treatment option for IAAA remains
unclear. This article aims to evaluate and compare outcomes of OSR and EVAR in IAAA repair.
Methods: All publications in the English language relating to IAAA were sought electronically
using OVID and MEDLINE (1972e2008). Studies identifying 30-day mortality were considered.
Periaortic inflammation (PAI), hydronephrosis and 1-year mortality were obtained from studies
with at least 1-year computed tomography (CT) follow-up. Outcomes of OSR and EVAR were
compared and analysed for statistical significance using Fisher’s exact test.
Results: The results were obtained from 35 studies comprising 999 patients and 21 studies with
121 patients who underwent OSR and EVAR, respectively. One-year CT follow-up was available
for 124 and 52 patients from the two groups, respectively. Thirty-day mortality after OSR was
6% (95% confidence interval (CI); 6e13) and 2% (95% CI; 0e7) after EVAR (pZ 0.1). At 1 year,
PAI regressed in 73% (95% CI; 64e80) in the OSR group compared to 65% (95% CI; 49e77) of the
EVAR group (pZ 0.7). Conversely, inflammation progressed in 1% and 4%, respectively
(pZ 0.1). Forty-five patients undergoing OSR and 29 EVAR were found to have preoperative
hydronephrosis. This regressed postoperatively in 69% (95% CI; 53.3e81.8) and 38% (95% CI;
20.6e57.7), respectively (pZ 0.01). Hydronephrosis progressed in 9% of patients after OSR
and in 21% after EVAR (pZ 0.1). New-onset hydronephrosis developed in 6% undergoing OSR
compared to 2% with EVAR (pZ 0.2). One-year all-cause mortality after OSR was 14% (95%
CI; 6e18) compared to 2% (95% CI; 0e13) after EVAR (pZ 0.02).
Conclusion: Either OSR or EVAR may be considered based on patient suitability. EVAR is asso-
ciated with lower 1-year mortality compared to OSR. However, OSR may be preferred in those
patients who have hydronephrosis and are deemed low risk.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.1 2764525; fax: þ44 161 2768014.
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Figure 1 Flow chart for selection of studies.described by Walker et al., in 1972, are characterised
by marked thickening of the aortic wall and perianeur-
ysmal fibrosis1 and account for 3e10% of all abdominal
aortic aneurysms (AAAs) with a male-to-female ratio
ranging from 9:1 to 30:1.2 IAAAs are associated with
smoking, a positive family history and autoimmune
diseases such as rheumatoid arthritis and systemic lupus
erythematosus.3,4
IAAAs are characterised by the presence of varying
degrees of inflammatory infiltrates within the aneurysmal
wall, the perivascular and the perineural tissues.1,5,6 These
infiltrates are predominantly constituted by plasma cells,
lymphocytes and macrophages. Genetic and environmental
aetiologies along with infections such as herpes simplex
and cytomegalovirus have been proposed in their
pathogenesis.3
Patients usually present at a younger age compared to
atherosclerotic aneurysms.2 The classical triad of abdom-
inal or back pain, weight loss and raised erythrocyte sedi-
mentation rate in patients with AAA is highly suggestive.2
Preoperative diagnosis can be established by ultrasound
scan (US), computed tomography (CT) scan, intravenous
urography (IVU) or gadolinium-enhanced magnetic reso-
nance imaging. US and IVU have low sensitivities (13.5% and
25e30%, respectively) compared to CT, which has a sensi-
tivity of up to 90% and is thus considered the gold stan-
dard.7,8 Perianeurysmal adhesions invariably involve the
duodenum, with additional involvement of the inferior vena
cava 70%, left renal vein 50%, ureter 44% and sigmoid colon
20%. Up to 20% of patients with ureteral entrapment
present with hydronephrosis.2
Traditionally, IAAAs have been treated by conventional
open surgical repair (OSR).2,7 Due to the potential for
iatrogenic injury in the presence of perianeurysmal adhe-
sions, some authors recommend modified approaches such
as avoidance of dissecting the duodenum and supracoeliac
cross-clamping of the aorta.9,10 Over the last 18 years,
endovascular aneurysm repair (EVAR) has emerged as
a treatment option and gained popularity due to favourable
perioperative morbidity and mortality compared to
OSR.11,13 It is, however, unclear whether EVAR has similar
benefit in patients with IAAA. Many individual series have
reported a regression of periaortic inflammatory process
with both OSR and EVAR. Hydronephrosis has also been
noted to regress postoperatively with both approaches,
though the extent is unknown.
To date, there are no randomised controlled trials
comparing OSR and EVAR for IAAA. This systematic study
aims to evaluate current evidence for the outcomes of
inflammatory aneurysms treated by OSR and EVAR.
Further, the outcomes will be compared to determine
whether either approach has any advantage over the
other.
Methods
All publications in the English language related to IAAA,
using MESH words: abdominal aortic aneurysm, inflamma-
tion, surgery and endoluminal repair were sought using
OVID and MEDLINE. In order to maximise the search,luminal therapy were used as keywords. ‘Related articles’
command was used to further broaden the search. Refer-
ences of relevant publications were used to obtain addi-
tional studies. Searches included studies from 1972 to date.
The final search was conducted in May 2008. The flow chart
for selection of studies is shown in Fig. 1.
Outcome measures
- Thirty-day mortality: All studies presenting 30-day
mortality were included for review.
- Periaortic inflammation (PAI), hydronephrosis and
1-year mortality were recorded from studies with at
least 1-year CT follow-up.Inclusion and exclusion criteria
All studies presenting a minimum of 30-day follow-up data
after elective OSR and EVAR were included. For late PAI and
hydronephrosis, only studies presenting 1-year follow-up
results with a CT scan were included. Individual patient
data from the articles were reviewed and patients with less
than 1-year follow-up were excluded. Studies presenting
unclear follow-up data were also excluded. Results of
ruptured IAAA, thoracic and complex thoraco-abdominal
aneurysm morphologies were not considered. Studies with
follow-up other than CT were excluded.
Statistical analysis
Three authors (SP, JG and DM) independently reviewed the
abstracts of all relevant articles for inclusion. Any
discrepancy was resolved by FSI and MGW. Data were
collected (SP, JG) and analysed using STATSDIRECT statis-
tical software (version 2.6.8, Cheshire, UK). Outcomes of
OSR and EVAR were compared for statistical significance
using Fisher’s exact test; probability value less than 0.05
Table 1 Comparison of various outcome measures
between open and EVAR groups
Open repair EVAR p value
30-day mortality 6.2%
(nZ 999)
2.4%
(nZ 121)
0.1
Periaortic
inflammatory
process (%)
(nZ 124) (nZ 48)
Regression 73% 65% 0.3
Unchanged 26% 31% 0.5
Progression 1% 4% 0.1
Hydronephrosis (%) (Total nZ 85) (Total nZ 52)
Preoperative
hydronephrosis
nZ 45 nZ 29
Improved 69% 38% 0.01
Unchanged 22% 41% <0.05
Worsened 9% 21% 0.1
New onset 6% 2% 0.2
One-year mortality
All cause 14% 2% 0.01
Aneurysm related 2% 0% 0.3
OSR Versus EVAR in IAAA Repair 293was considered significant. All results are reported as
percentages and confidence intervals (CIs). As it was not
intended to perform a meta-analysis, standard tests for
heterogeneity and bias were not done.
Results
A total of 129 studies were identified of which 73 were
excluded. Of the remaining 56, only one study57 compared
OSR with EVAR; thirty-five studies were related to
OSR1,4,5,7e10,14e41 and 21 to EVAR11e13,42e58; 10 studies with
OSR and 13 studies with EVAR presented follow-up data
greater than 1-year duration. All the results are presented
in Table 1.Table 2 PAI and one-year mortality after OSR
Study (year) Number of
patients
Periaortic infl
Full regression
Baskerville (1987)17 1 1
Nachbur (1989)20 5 5
Bitsch (1997)28 19 17
Dimakakos (1999)33 10 10
Von Fritschen (1999)32 26 15
Speziale (2001)35 12 9
Pistolese (2002)36 7 6
Bonati (2003)38 18 18
Railo (2005)39 11 4
Yusuf (2007)40 15 5
Total 124 90 (73%)
a Aneurysm-related mortality is only 2%.Thirty-day mortality
Thirty-five studies comprising 999 patients and 21 with 121
patients reported 30-day mortality after OSR and EVAR,
respectively. Mortality rate was 6.2% (95% CI; 6e13) with
OSR and 2.4% (95% CI; 0e7) with EVAR (pZ 0.1).
Periaortic inflammation
One-year follow-up on PAI was reported in 124 patients
after OSR. Although 52 patients after EVAR with 1-year
follow-up were available, details of PAI were only available
in 48 patients. Only one study quantified the thickness of
periaortic inflammatory tissue,50 with the remainder only
reporting whether the inflammatory status persisted, pro-
gressed or regressed. Therefore for this analysis, PAI was
recorded as regressed, unchanged or progressed.
PAI regressed in 73% (95% CI; 64e80) after OSR and 65%
(95% CI; 49e77) after EVAR (Tables 2 and 4). Whilst PAI
remained unchanged in 26% and 31% after OSR and EVAR, it
progressed in 1% and 4%, respectively. None of the
observed differences between groups were statistically
significant.
Hydronephrosis
Seven studies after OSR18,29,33,36,37,40,43 and 11 after
EVAR17,28,32,35,36,39,59 comprising 85 and 52 patients,
respectively, reported the outcome of hydronephrosis.
Of those, preoperative hydronephrosis was noted in 45 and
29 patients, respectively. None of the studies presented
the grade of hydronephrosis.
Hydronephrosis regressed in 69% (95% CI; 53.3e81.8)
after OSR compared to 38% (95% CI; 20.6e57.7) after EVAR
(pZ 0.01) (Tables 3 and 5). Ten patients in OSR group had
concomitant ureterolysis, of whom improvement was noted
in seven patients. Regression in hydronephrosis after OSR
remained significantly higher compared to EVAR, on
excluding those 10 patients (pZ 0.01). Hydronephrosis
remained unchanged in 22% and 41%, respectively after OSR
and EVAR (pZ 0.1). Progression was noted in 9% (95% CI;ammation One-year
mortalityUnchanged Progression
e e e
e e e
2 e e
e e e
10 1 6
3 e e
1 e e
e e 5
7 e e
10 e 6
33 (26%) 1 (1%) 17 (14%)a
Table 3 Hydronephrosis after OSR
Study (year) Total number
of patients
Number of patients
with preoperative
hydronephrosis
Hydronephrosis
Improved Unchanged Progressed New onset
Baskerville (1987)17 3 e e e e 2
Bitsch (1997)28 19 7 7 e e e
Von Fritschen (1999)32 26 8 6 e 2 3
Speziale (2001)35 12 12 9 3 e e
Pistolese (2002)36 7 5 2 3 e e
Arroyo (2003)58 7 7 7 e e e
Railo (2005)39 11 6 e 4 2 e
Total 85 45 (53%) 31 (69%) 10 (22%) 4 (9%) 5 (6%)
294 S.C.V. Paravastu et al.2.4e21) and 21% (95% CI; 7.9e39.7), respectively (pZ 0.1).
New-onset hydronephrosis was noted in 6% after OSR and 2%
after EVAR (pZ 0.2).
One-year mortality
One-year mortality was reported in 23 studies. Whilst
aneurysm-related mortality was 2% and 0%, respectively,
with OSR and EVAR, all-cause mortality was 14% (95% CI;
6e18) and 2% (95% CI; 0e13), respectively after OSR and
EVAR (pZ 0.01).
Discussion
This is the first comprehensive review comparing both
30-day and 1-year outcomes of IAAA after OSR and EVAR.
These results demonstrate that both OSR and EVAR can be
safely performed in IAAA. Safety of EVAR in IAAA has also
been demonstrated in a recent meta-analysis, which
showed similar results of 30-day mortality, PAI and hydro-
nephrosis as above.60 More than 1-year follow-up data were
available in a minority of studies and therefore the status of
PAI and hydronephrosis as well as mortality after this period
remains unclear.Table 4 PAI and one-year mortality after EVAR
Study (year) Number of
patients
Periaortic in
Full regressi
Boyle (1997)43 1 1
Nevelsteen (1999)44 1 1
Villareal (2000)45 1 1
Barrett (2001)46 1 e
Parry (2001)48 1 1
Rehring (2001) 1 1
Vallabhaneni (2001)49 4 e
Deleersnijder (2002)50 7 3
Hinchliffe (2002)12 11 5
Puchner (2005)60 6 5
Hechelhammer (2005)53 10 9
Faizer (2005)54 4 4
Sueyoshi (2008)56 1 1
Total 49 23 (65%)
a Mortality secondary to acute respiratory distress syndrome.The results of this review show that 30-day mortality of
OSR and EVAR for IAAA were comparable to atherosclerotic
aneurysm repair. This suggests that although the aetiology
is unclear, perioperative mortality remains same, which
may be attributed to the fact that most of these series were
from high-volume centres. Although there was no signifi-
cant difference for 30-day mortality between OSR and EVAR
groups, this may be due to a type II error, as only 121
patients were in the EVAR group compared to 999 in OSR. It
is likely that the benefit of EVAR over OSR for IAAA will be
similar to that for non-inflammatory aneurysms. It is
interesting to note that 1-year mortality favoured EVAR.
The reasons for this are unclear since data provided
regarding co-morbidities were insufficient to allow such
a comparison between the two groups.
PAI is considered to be responsible for abdominal or
back pain and elevated ESR. Therefore, it is vital to
determine the status of postoperative PAI. PAI is seen as
a thickness from the tunica adventitia and is usually clearly
seen on a CT scan. Although only 12% of OSR patients had
CT follow-up, the available data showed that PAI regressed
with both OSR and EVAR. However, contrary to the
conventional belief that PAI completely regresses after
OSR, this was noted in only 38%. This was akin to PAI
regression noted following EVAR. Since there has beenflammation One-year
mortalityon Unchanged Progression
e e e
e e e
e e e
e 1 e
e e e
e e e
3 1 e
4 e
6 e e
1 e 1
1 e e
e e e
e e e
15 (31%) 2 (4%) 1 (2%)a
Table 5 Hydronephrosis after EVAR
Study (year) Total number
of patients
Number of patients
with preoperative
hydronephrosis
Hydronephrosis
Improved Unchanged Progressed New onset
Boyle (1997)43 1 1 e 1 e e
Nevelsteen (1999)44 1 1 1 e e e
Barrett (2001)46 1 1 1 e e e
Rahring (2001) 1 1 1 e e e
Vallabhaneni (2001)49 4 3 1 1 1 1
Deleersnijder (2002)50 5 5 2 3 e e
Hinchliffe (2002)12 11 6 1 3 2 e
Puchner (2005)60 6 2 1 1 e e
Lange (2005)52 11 5 e 2 3 e
Hechelhammer (2005)53 10 3 3 e e e
Meester (2006)59 1 1 e 1 e e
Total 52 29 (58%) 11 (38%) 12 (41%) 6 (21%) 1 (2%)
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triggers the development of IAAA,3,61 it may be hypoth-
esised from these results that regression of the inflam-
matory process is dependent on aneurysm exclusion rather
than the type of surgery. The degree of regression in PAI
could not be quantified as only one study presented the
baseline thickness of PAI. Whilst the studies have reported
on postoperative periaortic thickening, none commented
on patient symptomatology.
A significant number of patients undergoing OSR had
regression of their hydronephrosis compared to EVAR. This
finding remained significant even when 10 patients who
underwent ureterolysis in the OSR group were excluded.
This finding questions the need for routine ureterolysis
advocated by the Swedish registry.25 Regression in hydro-
nephrosis after EVAR as shown in some series could be
a slow process.11 Further, it is unclear whether EVAR alone
has any beneficial effect on hydronephrosis, given the fact
that in half of the number of patients, regression was noted
only after initiating steroid therapy (Table 6).
Secondary intervention rate after EVAR was 22% and was
due to the following reasons. One patient developed aorto-
enteric fistula (2%) 8 months post-EVAR, which was treated
successfully by performing an aorto-bi-femoral bypass after
removing the infected stent graft. Four patients developed
type III endoleak (8%) and three, type II endoleak (6%). Two
patients had graft thrombosis (4%) and one patient devel-
oped stenosis of the graft (2%). These complication rates
seem higher compared to the mid-term results of EVAR trial
1,62 where type II endoleak in 3% and type III endoleak in 1%
(nZ 505) was observed. Graft thrombosis and stenosis
were noted in 2.5% and 0.2%, respectively. It is unclearTable 6 Comparison of EVAR alone versus EVARþ steroids
Treatment Number of patients with
preoperative
hydronephrosis
EVAR alone 20
EVARþ steroids 9whether increased incidence of complications in IAAA is
secondary to the inflammatory nature of the aneurysm. A
recent publication from EUROSTAR registry showed that
IAAAs treated by EVAR have a higher incidence of stent
stenosis compared to non-inflammatory aneurysms: 3.9%
versus 0.3%, respectively. Progression of periaortic fibrosis
may be a cause; however, such data were unavailable.
Alternately, it may be a chance finding as the authors
compared 52 inflammatory aneurysms with 3613 non-
inflammatory aneurysms.52
Traditionally, IAAAs have been treated by OSR as it was
thought that inflammatory process would regress, and in
presence of ureteral entrapment, concomitant ureterolysis
could be performed. OSR for IAAA can pose a technical
challenge depending on the degree of inflammation and
the involvement of adjacent organs. EVAR has been
increasingly employed in recent years due to low peri-
operative morbidity and mortality in non-inflammatory
aneurysms. EVAR can also be of advantage in patients with
hostile abdomen. This systematic study shows that OSR or
EVAR can be performed; however, the results are limited
by the non-availability of randomised controlled trials or
case control studies comparing OSR with EVAR. Further,
most of the studies were retrospective reviews. A number
of case reports were included which may have led to
selection bias. Furthermore, it should be noted that only
12% after OSR had CT follow-up, which may have under-
estimated the true regression or progression of PAI and
hydronephrosis. Besides this, surgical technique and peri-
operative patient care have improved over decades and
this may have confounded the results, especially of the
OSR group.Hydronephrosis
Improved Unchanged Progressed
6 (30%) 9 (45%) 5 (25%)
6 (67%) 2 (22%) 1 (11%)
296 S.C.V. Paravastu et al.Conclusions
Either OSR or EVAR may be considered based on patient
suitability. EVAR is associated with lower 1-year mortality
compared to OSR. However, OSR may be preferred in those
patients who have hydronephrosis and are deemed low
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